Access DB# 122216

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: S. Kumar Examiner #: 69591 Date: 5/17/03
Art Unit: 1621 Phone Number 30 272-0640 Serial Number: 10/023,933
Mail Box and Bldg/Room Location: REM 5D61 Results Format Preferred (circle): PAPER DISK E-MAIL
5C18

If more than one search is submitted, please prioritize searches in order of need. MEJ

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: New Oxybenzamide derivatives useful for inhibiting factor Xa or VIIa

Inventors (please provide full names): Marc Nazare et al

Earliest Priority Filing Date: 12/22/2000

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**

$R^0-Q-X-Q'-W-U-V-G-M$

A^0 is monocyclic or bicyclic aryl or heteroaryl

Q & Q' are bond, $((CH_2)_1-O-CH_2)_3$, NR etc

X bond, heteroaryl, alkylene etc.

W aryl, heteroaryl

R^1 H, NO2, CN etc.

U & G are $(CH_2)_m$, etc.

M H, alkyl etc.

V bond, alkylene



Specific: See claims & especially claim 10

****

STAFF USE ONLY

Searcher: Beverly 82528
Searcher Phone #:
Searcher Location:
Date Searcher Picked Up:
Date Completed: 05-19-04
Searcher Prep & Review Time:
Clerical Prep Time:
Online Time:

Type of Search

NA Sequence (#)
AA Sequence (#)
Structure (#)
Bibliographic
Litigation
Fulltext
Patent Family
Other

Vendors and cost where applicable

STN
Dialog
Questel/Orbit
Dr.Link
Lexis/Nexis
Sequence Systems
WWW/Internet
Other (specify)

PTO-1590 (8-01)

Kumar, S.
10/023933

(FILE 'REGISTRY' ENTERED AT 11:10:37 ON 19 MAY 2004)
L3 STR



Species

VAR G1=C/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE
L5 20 SEA FILE=REGISTRY SSS FUL L3

100.0% PROCESSED 27 ITERATIONS 20 ANSWERS
SEARCH TIME: 00.00.01

(FILE 'HCAPLUS' ENTERED AT 11:30:59 ON 19 MAY 2004)
L6 1 S L5

L6 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:486185 HCAPLUS
DOCUMENT NUMBER: 137:63256
TITLE: Preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa.
INVENTOR(S): Nazare, Marc; Will, David William; Peyman, Anuschirwan; Matter, Hans; Zoller, Gerhard; Gerlach, Uwe
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: Eur. Pat. Appl., 101 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1217000	A1	20020626	EP 2000-128477	20001223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2002051831	A1	20020704	WO 2001-EP14842	20011215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1349847	A1	20031008	EP 2001-272016	20011215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300306	A	20031015	EE 2003-306	20011215
BR 2001016473	A	20040113	BR 2001-16473	20011215
US 2002198195	A1	20021226	US 2001-23933	20011221
NO 2003002820	A	20030821	NO 2003-2820	20030619

PRIORITY APPLN. INFO.: EP 2000-128477 A 20001223
WO 2001-EP14842 W 20011215

OTHER SOURCE(S): MARPAT 137:63256

AB RQXQ1WUVGM [R = (substituted) aryl, heteroaryl; Q, Q1 = bond, CO, O, S, imino, carbonylimino, SO, SO2, (substituted) alkylene, etc.; X = bond, heteroaryl, (substituted) alkylene, heteroalkylene; W = (substituted) aryl, heteroaryl, mono-, polycyclic group; U, G = bond, (CH2)m, (CH2)mO(CH2)n, (CH2)mCO(CH2)n, (CH2)mS(CH2)n, etc.; m, n = 0-6; V = bond, (substituted) alkylene, aryl, heteroaryl, cyclic group; M = H, alkyl, (substituted) alkylaminocarbonyl, aryl, heteroaryl, cyclic group; with provisos], were prepared Thus, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxybenzoic acid, N-NEM, 1-(pyridin-4-ylmethyl)piperazine, and TOTU were stirred in DMF to give [3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxyphenyl](4-pyridin-4-ylmethylpiperazin-1-yl)methanone. The latter inhibited factor Xa with Ki = 0.600 μM.

IT **438570-10-6P 438570-12-8P 438570-14-0P**
438570-24-2P 438570-61-7P 438570-63-9P
438570-68-4P 438570-69-5P 438570-79-7P
438570-80-0P 438570-81-1P 438570-82-2P
438570-83-3P 438570-85-5P 438570-86-6P
438570-88-8P 438570-90-2P 438570-91-3P
438570-94-6P 438571-00-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

RN 438570-10-6 HCAPLUS

CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4,5-dimethoxy-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-12-8 HCAPLUS
CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-14-0 HCAPLUS
CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-ethoxy-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-24-2 HCAPLUS
CN Benzamide, 4-bromo-3-[2-(2,4-dichlorophenyl)ethoxy]-5-methoxy-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-61-7 HCAPLUS

CN Benzamide, N-([1,4'-bipiperidin]-4-ylmethyl)-3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 438570-63-9 HCAPLUS
CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxy-N-[[1-(2-methyl-4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-68-4 HCAPLUS
CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxy-N-[[1-(1-oxido-4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-69-5 HCAPLUS
CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxy-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-79-7 HCAPLUS

CN Benzamide, 4-bromo-3-[2-(2,4-dichlorophenyl)ethoxy]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-80-0 HCAPLUS
CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-methyl-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-81-1 HCAPLUS
CN Benzamide, 4-amino-3-[2-(2,4-dichlorophenyl)ethoxy]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-82-2 HCAPLUS
CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-fluoro-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-83-3 HCAPLUS

CN Benzamide, 2-chloro-5-[2-(2,4-dichlorophenyl)ethoxy]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-85-5 HCAPLUS
CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-5-methoxy-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-86-6 HCAPLUS
CN Benzamide, 5-[2-(2,4-dichlorophenyl)ethoxy]-2-nitro-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-88-8 HCAPLUS
CN Benzamide, 4-bromo-3-[2-(2,4-dichlorophenyl)ethoxy]-5-hydroxy-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-90-2 HCAPLUS
CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 438570-91-3 HCAPLUS
CN Benzamide, 4-cyano-3-[2-(2,4-dichlorophenyl)ethoxy]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-94-6 HCAPLUS
CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-(methylthio)-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438571-00-7 HCAPLUS
CN 1,3-Benzenedicarboxamide, 5-[2-(2,4-dichlorophenyl)ethoxy]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

FILE 'CAOLD' ENTERED AT 11:32:34 ON 19 MAY 2004
L7 0 S L5

FILE 'USPATFULL' ENTERED AT 11:32:42 ON 19 MAY 2004
L8 1 S L5

L8 ANSWER 1 OF 1 USPATFULL on STN
ACCESSION NUMBER: 2002:344465 USPATFULL
TITLE: New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa
INVENTOR(S): Nazare, Marc, Eppstein, GERMANY, FEDERAL REPUBLIC OF
Will, David William, Kriftel, GERMANY, FEDERAL REPUBLIC OF
Peyman, Anuschirwan, Kelkheim, GERMANY, FEDERAL REPUBLIC OF
Matter, Hans, Langenselbold, GERMANY, FEDERAL REPUBLIC OF
Zoller, Gerhard, Schoneck, GERMANY, FEDERAL REPUBLIC OF
Gerlach, Uwe, Hattersheim, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002198195	A1	20021226	
APPLICATION INFO.:	US 2001-23933	A1	20011221	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2000-128477	20001223

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 7503

Searcher : Shears 571-272-2528

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds comprising the following formula:

R.sup.0--Q--X--Q'--W--U--V--G--M (I)

These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

(FILE 'MARPAT' ENTERED AT 11:33:02 ON 19 MAY 2004)

L9 STR



VAR G1=C/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L11 1 SEA FILE=MARPAT SSS FUL L9 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 2288 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.12

L11 ANSWER 1 OF 1 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 137:63256 MARPAT
TITLE: Preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa.
INVENTOR(S): Nazare, Marc; Will, David William; Peyman, Anuschirwan; Matter, Hans; Zoller, Gerhard; Gerlach, Uwe
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: Eur. Pat. Appl., 101 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1217000	A1	20020626	EP 2000-128477	20001223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2002051831	A1	20020704	WO 2001-EP14842	20011215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1349847	A1	20031008	EP 2001-272016	20011215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300306	A	20031015	EE 2003-306	20011215
BR 2001016473	A	20040113	BR 2001-16473	20011215
US 2002198195	A1	20021226	US 2001-23933	20011221
NO 2003002820	A	20030821	NO 2003-2820	20030619
PRIORITY APPLN. INFO.:			EP 2000-128477	20001223
			WO 2001-EP14842	20011215

AB RQXQ1WUVGM [R = (substituted) aryl, heteroaryl; Q, Q1 = bond, CO, O, S, imino, carbonylimino, SO, SO2, (substituted) alkylene, etc.; X = bond, heteroaryl, (substituted) alkylene, heteroalkylene; W = (substituted) aryl, heteroaryl, mono-, polycyclic group; U, G = bond, (CH2)m, (CH2)mO(CH2)n, (CH2)mCO(CH2)n, (CH2)mS(CH2)n, etc.; m, n = 0-6; V = bond, (substituted) alkylene, aryl, heteroaryl, cyclic

group; M = H, alkyl, (substituted) alkylaminocarbonyl, aryl, heteroaryl, cyclic group; with provisos], were prepared Thus, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxybenzoic acid, N-NEM, 1-(pyridin-4-ylmethyl)piperazine, and TOTU were stirred in DMF to give [3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxyphenyl](4-pyridin-4-ylmethylpiperazin-1-yl)methanone. The latter inhibited factor Xa with Ki = 0.600 μM.

IC ICM C07D401-00
ICS C07D213-30; C07D333-16; C07D333-58; A61K031-38; A61K031-435

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

ST heterocyclyl benzamide blood coagulation factor inhibitor; cardiovascular agent heterocyclyl benzamide prepn

IT Respiratory distress syndrome
(adult, treatment; preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT Heart, disease
(angina pectoris, treatment of unstable angina; preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT Artery, disease
(coronary, treatment; preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT Heart, disease
(infarction, treatment; preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT Brain, disease
(ischemia, transient, treatment; preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT Anti-inflammatory agents
Anticoagulants
Antitumor agents
Antiviral agents
Cardiovascular agents
(preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT Artery, disease
(restenosis, treatment; preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT Shock (circulatory collapse)
(septic, treatment; preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT Brain, disease
(stroke, treatment; preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT Embolism
(thromboembolism, treatment; preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT Blood coagulation
Cardiovascular system, disease
Fibrinolysis
Inflammation
Multiple organ failure
Neoplasm
(treatment; preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT Infection
(viral, treatment; preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT 9002-05-5, Factor xa 65312-43-8, Factor viia
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT 438570-05-9P 438570-06-0P 438570-07-1P 438570-08-2P
438570-09-3P 438570-10-6P 438570-11-7P 438570-12-8P
438570-13-9P 438570-14-0P 438570-15-1P 438570-16-2P
438570-17-3P 438570-18-4P 438570-19-5P 438570-20-8P
438570-21-9P 438570-22-0P 438570-23-1P 438570-24-2P
438570-25-3P 438570-26-4P 438570-27-5P 438570-28-6P
438570-29-7P 438570-30-0P 438570-31-1P 438570-32-2P
438570-33-3P 438570-34-4P 438570-35-5P 438570-36-6P
438570-37-7P 438570-38-8P 438570-39-9P 438570-40-2P
438570-41-3P 438570-42-4P 438570-43-5P 438570-44-6P
438570-45-7P 438570-46-8P 438570-47-9P 438570-48-0P
438570-49-1P 438570-50-4P 438570-51-5P 438570-52-6P
438570-53-7P 438570-54-8P 438570-55-9P 438570-56-0P
438570-57-1P 438570-58-2P 438570-59-3P 438570-60-6P
438570-61-7P 438570-62-8P 438570-63-9P 438570-64-0P
438570-65-1P 438570-66-2P 438570-67-3P 438570-68-4P
438570-69-5P 438570-70-8P 438570-71-9P 438570-72-0P
438570-73-1P 438570-74-2P 438570-75-3P 438570-76-4P
438570-77-5P 438570-78-6P 438570-79-7P 438570-80-0P
438570-81-1P 438570-82-2P 438570-83-3P 438570-84-4P
438570-85-5P 438570-86-6P 438570-87-7P 438570-88-8P
438570-89-9P 438570-90-2P 438570-91-3P 438570-92-4P
438570-93-5P 438570-94-6P 438570-95-7P 438570-96-8P
438570-97-9P 438570-98-0P 438570-99-1P 438571-00-7P
438583-13-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT 68-35-9 99-06-9, 3-Hydroxybenzoic acid, reactions 106-39-8, 4-Bromochlorobenzene 108-86-1, Bromobenzene, reactions 120-92-3, Cyclopentanone 459-46-1, 1-(Bromomethyl)-4-fluorobenzene 1008-91-9 1072-98-6 1514-87-0, Methyl chlorodifluoroacetate 1538-75-6, Pivalic anhydride 1822-51-1 1916-08-1 2549-93-1, 1,4-Cyclohexanedimethanamine 2675-89-0, 2-Chloro-N,N-dimethylacetamide 2706-56-1, 2-Pyridin-2-ylethylamine 2766-74-7 3529-08-6, 3-Piperidin-1-ylpropylamine 3678-63-5, 4-Chloro-2-picoline 3943-89-3, Ethyl 3,4-dihydroxybenzoate 10394-38-4 13258-63-4, 4-Pyridineethanamine 13472-85-0, 5-Bromo-2-methoxypyridine 14348-38-0, 4-Bromo-3-hydroxybenzoic acid 16498-81-0, 2-Methoxynicotinic acid 17201-43-3, 4-(Bromomethyl)benzonitrile 19438-10-9, 3-Hydroxybenzoic acid methyl ester 19524-06-2, 4-Bromopyridine hydrochloride 27578-60-5, 2-Piperidin-1-ylethylamine 31462-56-3 39178-35-3 39890-45-4 55579-01-6 57260-71-6 62089-74-1 81156-68-5, 2-(2,4-Dichlorophenyl)ethanol 91323-34-1 144222-22-0, tert-Butyl 4-aminomethylpiperidine-1-carboxylate 149898-87-3 153863-92-4, Furo[3,2-c]pyridine-2-methanamine 156972-83-7 166954-15-0

323594-39-4 335439-70-8 335439-76-4 435321-22-5 438571-19-8
438571-20-1 438571-21-2 438571-22-3 438571-23-4 438571-24-5
438571-25-6 438571-26-7 438571-27-8 438583-12-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT 58123-77-6P, 3-Hydroxy-4-iodobenzoic acid 83011-43-2P, Methyl 3-hydroxy-4,5-dimethoxybenzoate 106291-80-9P 157942-12-6P
382150-30-3P 435321-16-7P 438571-01-8P 438571-02-9P
438571-03-0P 438571-04-1P 438571-05-2P 438571-06-3P
438571-07-4P 438571-08-5P 438571-09-6P 438571-10-9P
438571-11-0P 438571-12-1P 438571-13-2P 438571-14-3P
438571-15-4P 438571-16-5P 438571-17-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

FILE 'MARPATPREV' ENTERED AT 11:34:00 ON 19 MAY 2004

L9 STR



VAR G1=C/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:

ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L12 0 SEA FILE=MARPATPREV SSS FUL L9 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 7 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

(FILE 'CASREACT' ENTERED AT 11:34:27 ON 19 MAY 2004)
L3 STR



VAR G1=C/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE
L14 0 SEA FILE=CASREACT SSS FUL L3 (0 REACTIONS)

100.0% DONE 0 VERIFIED 0 HIT RXNS 0 DOCS
SEARCH TIME: 00.00.01

(FILE 'DJSMDS, CHEMINFORMRX' ENTERED AT 11:35:21 ON 19 MAY 2004)
L3 STR



VAR G1=C/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE
L15 0 SEA L3

FILE 'HOME' ENTERED AT 11:35:45 ON 19 MAY 2004